Imagen de Portada

Editorial: How does the risk of hepatocellular carcinoma change over time in patients with a hepatitis C cure? Authors' reply

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Philip Vutien, Nicole J. Kim, Andrew M. Moon, Kay M. Johnson, Kristin Berry, Pamela K. Green, George N. Ioannou
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Alimentary Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance
por: Hye Won Lee, et al.
Publicado: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
por: Hyeyeon Hong, et al.
Publicado: (2024)

Editorial: Quantity is important! Authors' reply
por: Marika Rudler, et al.
Publicado: (2024)

Editorial: Genetics for non‐invasive risk stratification—Finding the needle in the haystack? Authors' reply
por: Lana Bridi, et al.
Publicado: (2024)

Letter: Association of persistently high HBsAg levels during HBeAg‐seropositive stage and hepatocellular carcinoma risk in chronic hepatitis B patients
por: Jian Wang, et al.
Publicado: (2024)

Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes
por: Xianhua Mao, et al.
Publicado: (2024)

Editorial: Unravelling real‐world impact of second‐line therapies in primary biliary cholangitis—Time to change our targets? Authors' reply
por: C. M. Fernández‐Rodríguez, et al.
Publicado: (2024)

Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response
por: Jung Eun Park, et al.
Publicado: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
por: David Bergman, et al.
Publicado: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
por: Kyle Staller, et al.
Publicado: (2024)

Editorial: Another brick in the CDST wall: Authors' reply
por: Kyuwon Kim, et al.
Publicado: (2024)

Editorial: Sonographic assessment of colonic content—A new tool for constipation? Authors' reply
por: R. M. Mathias, et al.
Publicado: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
por: Eiichi Ogawa
Publicado: (2024)

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply
por: Marcus M. Mücke, et al.
Publicado: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
por: Carolin V. Schneider, et al.
Publicado: (2024)

Editorial: Recompensation in PBC is good. But is it good enough? Authors' reply
por: Benedikt Silvester Hofer, et al.
Publicado: (2024)

Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV cure programme. Authors' reply
por: Chan Xie
Publicado: (2024)

Editorial: The microbiome and gastric mucosal protection in aspirin users—Authors' reply
por: Nina Løn, et al.
Publicado: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
por: Annalisa Schiepatti, et al.
Publicado: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
por: Stuart McPherson, et al.
Publicado: (2024)

Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply
por: S. K. Bansal, et al.
Publicado: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
por: Matthias Lenfant, et al.
Publicado: (2024)

Editorial: Can we predict or not predict response to hypnotherapy? That is the question. Authors' reply
por: Dipesh H. Vasant, et al.
Publicado: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
por: Abhinav Vasudevan, et al.
Publicado: (2024)

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply
por: Matthias Lenfant, et al.
Publicado: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
por: Elliot B. Tapper, et al.
Publicado: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
por: Jessica A. Fitzpatrick, et al.
Publicado: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
por: Linda Henry, et al.
Publicado: (2024)

Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis? Authors' reply
por: Yu Liu, et al.
Publicado: (2024)

Psychiatric disorders in patients with hepatocellular carcinoma: A large US cohort of commercially insured individuals
por: Mausam J. Patel, et al.
Publicado: (2024)

Letter: Over‐the‐scope clips in patients at high risk of rebleeding following upper gastrointestinal tract bleeding—The magic bullet for everyone? Authors'reply
por: Kai Song, et al.
Publicado: (2024)

Editorial: Mortality in immune‐mediated inflammatory diseases during early adulthood—Authors' reply
por: Mikkel Malham, et al.
Publicado: (2024)

Editorial: Emulsifiers and thickeners in our food—Do they alter gut permeability? Authors' reply
por: Jessica A. Fitzpatrick, et al.
Publicado: (2024)

Editorial: High qHBsAg—Is it a good or bad signal? Authors' reply
por: Hsin‐Che Lin, et al.
Publicado: (2024)

Editorial: Hepatitis C virus eradication improves skeletal muscle mass—Authors' reply
por: Marta Paula Pereira Coelho, et al.
Publicado: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
por: Arta Aliu, et al.
Publicado: (2024)

Editorial: Mucosal healing with steroids—Once upon a time in ulcerative colitis. Authors' reply
por: Tomohiro Fukuda, et al.
Publicado: (2024)

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
por: Manya Prasad, et al.
Publicado: (2024)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
por: María José García, et al.
Publicado: (2024)

Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
por: Akshatha Kiran, et al.
Publicado: (2024)